MedTrace Logo

Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects

NCT04480697 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2022-04-25

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HPG1860 orally administered in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

HPG1860

6 subjects randomized to active compound and 2 subjects randomized to placebo

Sponsors & Collaborators

  • Hepagene (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-23
Primary Completion
2020-11-25
Completion
2021-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04480697 on ClinicalTrials.gov